Markets
markets

Pfizer to buy obesity drug developer Metsera for up to $7.3 billion

Pfizer rose in premarket trading after it announced that it would acquire anti-obesity drug developer Metsera, which puts the pharmaceutical giant back in the weight-loss medication game after its own pill didn’t advance to the final stages of trials.

The transaction is a valued at $47.50 per share (roughly $4.9 billion by enterprise value), which could rise to $70 per share (or $7.3 billion) if certain clinical and regulatory milestones are met. Metsera closed at $33.32 on Friday and shot up nearly 60% in premarket trading.

The deal, which was paid for with a combination of cash and debt, is expected to close by the end of the year.

Metsera is developing a weight-loss shot (called MET-233i) that has shown promise but is still in early trials, meaning it will likely be years before it reaches patients. Notably, the shot is able to be taken monthly rather than weekly like the GLP-1 shots currently on the market made by Eli Lilly and Novo Nordisk.

More Markets

See all Markets
markets

Fluence Energy keeps surging after hyperscaler supply agreements outweigh soft quarter

Fluence Energyis building on Thursday’s massive gains in the premarket on Friday amid optimism about data center demand for its energy storage solutions.

Though the company delivered underwhelming Q2 results after the close on Wednesday, management announced the signing of new master supply agreements with two major hyperscalers and expects to convert its first order soon. During the conference call, CEO Julian Nebreda indicated that the company has a 12 gigawatt pipeline tied to data center projects.

Analysts at JPMorgan, Canaccord, Jefferies, Goldman Sachs, and Roth Capital raised their price targets on Fluence in the wake of this news.

“The sentiment on FLNC was negative going into the quarter and the hyperscaler announcement came sooner than expected,” noted Citi analyst Vikram Bagri, per Bloomberg.

markets

Innodata soars after company boosts full-year sales guidance, delivers impressive Q1 results

Innodata is surging in premarket trading after announcing better than expected quarterly results and raising its full-year sales guidance.

The data engineering company is seemingly benefitting from demand for its expertise to help improve the capabilities of AI tools.

The key numbers for Q1:

  • Revenue: $90.1 million (estimate: $76.5 million)

  • Adjusted EBITDA: $25.0 million (estimate: $10.4 million)

Innodata raised its full-year revenue growth guidance to around 40% or more, up from the around 35% or more guidance it gave out ten weeks ago.

CEO Jack Abuhoff described this outlook as “prudent,” noting that several potentially large programs have not yet been included in this forecast.

To that end, he noted a new set of engagements with a large technology company that, if solidified, would generate approximately $51 million of revenue in 2026. Management is currently in discussions with an additional 15 companies and two hyperscalers about its new platform for agentic systems, Abuhoff added.

Earlier this year, this company announced a pact to provide data and data engineering services to Palantir to help improve AI tools that analyzed rodeos.

The robust quarter and outlook are bringing shares of Innodata back into the green on the year after having been down 10% heading into this report.

A South Korean national flag (L) with a Samsung Group flag (

South Korea surges past Canada to become the seventh-largest stock market in the world amidst AI boom

The country’s two chip giants have seen their shares more than double this year.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.